Corona Remedies IPO to Open on December 8, 2025: Check Lot Size, Price Band & Key Details
The Initial Public Offering (IPO) for Corona Remedies is opening on December 8, 2025, with an issue size of ₹655.37 crores. Earlier this week, on December 2, 2025, the company filed its Red Herring Prospectus (RHP) for its IPO. The issue will be entirely an offer for sale, and the public subscription window will remain open till December 10, 2025.
The allotment process for Corona Remedies IPO is expected to be finalised on December 11, 202,5, and the shares will be listed on both NSE and BSE. The tentative listing date is fixed as December 12, 2025.
Corona Remedies Ltd is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other therapeutic areas. Dr Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, and Ankur Kirtikumar Mehta are the Promoters of the Company.
Corona Remedies IPO - Issue Details
- Issue Structure: As per the RHP, the Corona Remedies IPO will be a book-building issue of ₹655.37 crores consisting entirely of an offer-for-sale of 0.62 crore shares.
- Price Band: The price band is set between ₹1008 and ₹1062 per share.
- Lot Size (for retail investors): 14 shares per lot.
- Minimum Investment (for retail investors): ₹14,868 (14 shares) as per the upper band.
- Book-running Lead Managers: JM Financial Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) and Kotak Mahindra Capital Company Limited are the book-running lead managers for the Corona Remedies Ltd IPO.
- Registrar: Bigshare Services Private Limited.
Explore other Upcoming IPOs on BSE and NSE.
Use of Proceeds
The Company will not receive any proceeds from the Offer (“Offer Proceeds”), and the Offer Proceeds will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer, after deducting their portion of the Offer-related expenses and the relevant taxes thereon.
Check out newly Listed IPOs on BSE and NSE.
About Corona Remedies Ltd
Corona Remedies Ltd is an Ahmedabad-based pharmaceutical company incorporated in August 2004. It develops, manufactures, and markets a broad range of drug formulations, including oral solids, capsules, syrups, and other dosage forms, across therapeutic segments such as women’s healthcare, cardiology, diabetes, pain management, urology, anti-infectives, vitamins, and nutraceuticals.
Corona Remedies operates from two manufacturing facilities, one in Gujarat (Bhayla) and another in Himachal Pradesh (Solan). Altogether, they house 11 production lines capable of handling complex drug manufacturing and delivery systems.
Financially, for the year ended March 31, 2025, Corona Remedies generated revenue of approximately ₹1,200 crore. In FY24, the company had a net profit margin of roughly 8.9%, with an operating margin (EBITDA level) of about 15.4%.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.